Studies of bortezomib, thalidomide, and lenalidomide have shown promising clinical
activity in relapsed/refractory multiple myeloma (MM). Bortezomib alone and in combination
with other agents is associated with high response rates, consistently high rates
of complete response, and a predictable and manageable profile of adverse events.
Thalidomide-based regimens have also shown substantial clinical activity. The accumulating
experience from ongoing trials of bortezomib/lenalidomide/dexamethasone combinations
in patients who have relapsed/refractory or newly diagnosed MM will provide critical
information that will determine the possible role of this combination as the basic
backbone for combination regimens for management of advanced MM.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.Blood. 1986; 67: 1298
- High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.Blood. 1987; 70: 869
- High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants.J Clin Oncol. 2006; 24: 426S
- A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med. 2003; 348: 2609
- High-dose glucocorticoid treatment of resistant myeloma.Ann Intern Med. 1986; 105: 8
- Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010).Blood. 2005; 106: 6A
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med. 2005; 352: 2487
- Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009).J Clin Oncol. 2006; 24: 7521
- A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma.Leukemia. 1995; 9: 2115
- Effective treatment of advanced multiple myeloma refractory to alkylating agents.N Engl J Med. 1984; 310: 1353
- VAD chemotherapy as remission induction for multiple myeloma.Br J Cancer. 1995; 71: 326
- Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study.J Clin Oncol. 2006; 24: 423S
- Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.Am J Clin Oncol. 1995; 18: 475
- VAD chemotherapy for refractory multiple myeloma.Br J Haematol. 1989; 71: 25
- A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.Leuk Lymphoma. 1995; 17: 465
- Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma.Blood. 2005; 106: 717A
- Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.Lancet. 1992; 339: 200
- Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.J Clin Oncol. 1986; 4: 1227
- Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.Am J Hematol. 2000; 63: 125
- DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.J Clin Oncol. 2003; 21: 2732
- Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.Oncologist. 2003; : 39-45
- Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.Mayo Clin Proc. 2006; 81: 889
- Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.Ann Oncol. 2004; 15: 134
- Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.Ann Oncol. 2006; 17: 1766
- Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.Ann Hematol. 2007; 86: 211
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.Blood. 2005; 105: 3058
- Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.Clin Lymphoma Myeloma. 2007; 7: 266
- Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.Blood. 1993; 82: 2324
- Early myeloablative therapy for multiple myeloma.Blood. 1994; 84: 4278
- Limited value of myeloablative therapy for late multiple myeloma.Blood. 1994; 83: 512
- High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.Blood. 1998; 92: 3131
- Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.Br J Haematol. 2003; 123: 484
- Transplantation as salvage therapy for high-risk patients with myeloma in relapse.Bone Marrow Transplant. 2002; 30: 873
- Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.Blood. 2007; 109: 3588
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.Blood. 2003; 102: 3447-3454
- Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.Biol Blood Marrow Transplant. 2003; 9: 312-319
- Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.Biol Blood Marrow Transplant. 2004; 10: 698
- Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci U S A. 1994; 91: 4082
- Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol. 1994; 87: 503
- Lenalidomide and thalidomide: mechanisms of action–similarities and differences.Semin Hematol. 2005; 42: S3
- Phase I trial of bortezomib (V) in combination with “DT-PACE”: toxicity, stem cell collection and engraftment in newly diagnosed multiple myeloma (MM) patients (Pts).Blood. 2005; 106: 771A
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood. 2001; 98: 210
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000; 96: 2943
- Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood. 2002; 99: 4525
- Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med. 1999; 341: 1565
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.Blood. 2001; 98: 492
- Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.Semin Hematol. 2003; 40: 3
- A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.Haematologica. 2004; 89: 552
- An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.Br J Cancer. 2004; 91: 1873
- Thalidomide treatment of resistant or relapsed multiple myeloma patients.Haematologica. 2001; 86: 404
- Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.Mayo Clin Proc. 2003; 78: 34
- Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.Blood. 2003; 102: 69
- Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.Clin Cancer Res. 2002; 8: 3377
- Thalidomide in the treatment of relapsed multiple myeloma.Mayo Clin Proc. 2000; 75: 897
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Blood. 2005; 106: 4050
- An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.Leuk Res. 2003; 27: 909
- Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.Haematologica. 2001; 86: 409
- Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Haematologica. 2002; 87: 408
- Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.Br J Haematol. 2004; 125: 149
- Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy.Blood. 2005; 106: 231A
- Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas.Leukemia. 2005; 19: 143
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the Intergroupe Francophone du Myelome (IFM).Hematol J. 2002; 3: 185
- Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients.Blood. 2001; 98: 163A
- Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.Semin Hematol. 2003; 40: 33
- A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study.J Clin Oncol. 2006; 24: 427S
- Thalidomide alone or with dexamethasone for multiple myeloma.Blood. 1999; 94: 604A
- Thalidomide and dexamethasone for resistant multiple myeloma.Br J Haematol. 2003; 121: 768
- Thalidomide and dexamethasone combination for refractory multiple myeloma.Ann Oncol. 2001; 12: 991
- Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.Haematologica. 2001; 86: 399
- Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.Hematol J. 2004; 5: 318
- Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.Eur J Haematol. 2005; 75: 391
- Oral Revlimid (R) plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study.Blood. 2006; 108: 240A
- A randomized comparison of dexamethasone plus thalidomide (Dex/Thal) vs dex plus placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM).Blood. 2006; 108: 1017A
- Thalidomide in relapsed or refractory patients with multiple myeloma: monotherapy or combination therapy? A report from systematic reviews.Blood. 2005; 106: 364B
- Dermatologic side effects of thalidomide in patients with multiple myeloma.J Am Acad Dermatol. 2003; 48: 548
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: premilinary results of an IFM phase II study.J Clin Oncol. 2005; 23: 598S
- Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.Blood. 2001; 98: 3846
- Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.Haematologica. 2006; 91: 133
- The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.Leukemia. 2004; 18: 856
- Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.Hematol J. 2004; 5: 112
- Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.Br J Haematol. 2005; 129: 763
- Lenalidomide (Revlimid (TM)), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma—first results of a German multicenter phase I/II trial.Blood. 2006; 108: 125A
- Lenalidomide plus Bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial.ASH Annual Meeting Abstracts. 2006; 108: 405
- Approval summary for bortezomib for injection in the treatment of multiple myeloma.Clin Cancer Res. 2004; 10: 3954
- Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.Oncologist. 2003; 8: 508
- United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.Clin Cancer Res. 2006; 12: 2955
- The development of proteasome inhibitors as anticancer drugs.Cancer Cell. 2004; 5: 417
- Development of the proteasome inhibitor PS-341.Oncologist. 2002; 7: 9
- The proteasome: a suitable antineoplastic target.Nat Rev Cancer. 2004; 4: 349
- Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.Bioorg Med Chem Lett. 1998; 8: 333
- Proteasome inhibition: a new strategy in cancer treatment.Invest New Drugs. 2000; 18: 109
- Proteasome inhibitors: a novel class of potent and effective antitumor agents.Cancer Res. 1999; 59: 2615
- The proteasome as a target for cancer therapy.Clin Cancer Res. 2003; 9: 6316
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res. 2001; 61: 3071
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.Clin Cancer Res. 2003; 9: 1136
- Molecular sequelae of proteasome inhibition in human multiple myeloma cells.Proc Natl Acad Sci U S A. 2002; 99: 14374
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood. 2003; 101: 2377
- A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.Br J Haematol. 2004; 127: 165
- Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial.Cancer. 2006; 106: 1316
- Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial.Blood. 2005; 106: 715A
- Bortezomib in combination with dexamethasone for relapsed multiple myeloma.Leuk Res. 2005; 29: 587
- Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.Blood. 2005; 106: 716A
- A phase I-II trial of bortezomib (Veleade) (Vc) and oral cyclophosphamide (CY) plus prednisone (P) for relapsed/refractory multiple myeloma (MM).Blood. 2005; 106: 718A
- Weekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma.Blood. 2005; 106: 720A
- A new model predicting at least a very good partial response in patients with multiple myeloma after 2 cycles of velcade-based therapy.Haematologica. 2006; 91 ([abstract P.0741]): 273
- Combination therapy with velcade, doxil, and dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM).Blood. 2005; 106: 378B
- Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.J Clin Oncol. 2006; 24: 937
- A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma.Blood. 2005; 106: 718A
- Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.Blood. 2005; 106: 379B
- Combination therapy of bortezomib with low-dose bendamustine in elderly patients with advanced multiple myeloma.Blood. 2005; 106: 363B
- A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myelama.J Clin Oncol. 2006; 24: 449S
- Phase I study of bortezomib and Sm-153-lexidronam combination for refractory and relapsed multiple myeloma.J Clin Oncol. 2006; 24: 450S
- Phase 1 clinical trial of KOS-953+Bortezomib (BZ) in relapsed refractory multiple myeloma (MM).Blood. 2005; 106: 109a
- Bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide is an active salvage regimen in patients with relpase or refractory multiple myeloma: final results of a phase II trial.Haematologica. 2006; 91: 277
- Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): Long-term follow-up of Phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T.Blood. 2005; 106: 717A
- Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves response rate complete remission rate in patients with relapsed/refractory multiple myeloma.J Clin Oncol. 2006; 24 ([abstract 17537]) (68368s)
- Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma.Haematologica. 2006; 9: 281
- Bortezomib (Velcade (TM)) plus Adriamycin (TM) plus thalidomide plus dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM).Blood. 2004; 104: 659A
- Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.Blood. 2007; 109: 2767-2772
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1 alpha and angiogenic cytokines.Blood. 2006; 108: 1010A
- Intermediate-dose melphalan (100 mg/m2), bortezomib, thalidomide, dexamethasone and stem cell support in patients with refractory or relapsed myelome.Haematologica. 2006; 91: 88
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood. 2002; 100: 3063
- A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.Blood. 2005; 106: 449A
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood. 2006; 108: 3458
- Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.J Clin Oncol. 2006; 24: 3113
- Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial.Blood. 2005; 106: 111A
- PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.Br J Haematol. 2005; 129: 755
- A phase 1 trial of lenalidomide (REVLIMID (R)) with bortezomib (VELCADE (R)) in relapsed and refractory multiple myeloma.Blood. 2005; 106: 110A
- Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.Blood. 2005; 106: 3777
- Hematologic profiles in the phase 3 APEX trial.Blood. 2005; 106: 970A
- Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.Cancer. 2005; 104: 2141
- The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study.Blood. 2006; 108: 124A
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial.Blood. 2005; 106: 110A
- Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT).Blood. 2001; 98: 775A
- Lenalidomide (Len) in combination with dexamethasone (Dex) is more effective than Dex alone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma (MM).J Clin Oncol. 2006; 24: 446S
- Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma.Blood. 2006; 108: 1014A
- Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.Blood. 2006; 108: 1012A
- Use of lenalidomide (Revlimid (R) +/− corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels.Blood. 2006; 108: 1013A
- Antimyeloma activity of heat shock protein-90 inhibition.Blood. 2006; 107: 1092
- Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): interim results of a phase 1 trial.Blood. 2005; 106 (10910a)
- A multicenter phase 1 clinical trial of Tanespimycin (KOS-953) + Bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM).ASH Annual Meeting Abstracts. 2006; 108: 406
- Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group.Eur J Haematol. 1994; 53: 207
- Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.Eur J Haematol. 2000; 65: 175
- Bortezomib in recurrent and/or refractory multiple myeloma.Cancer. 2005; 103: 1195
- Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma.Blood. 2005; 106: 231A
- A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function.J Clin Oncol. 2006; 24: 87S
- Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis.Blood. 2005; 106: 716A
- Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients.J Clin Oncol. 2005; 23: 612S
- Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.Eur J Haematol. 2004; 73: 98
- Thalidomide in patients with multiple myeloma and renal failure.Br J Haematol. 2004; 125: 96
- Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.Br J Haematol. 2003; 122: 160
REVLIMID (lenalidomide) Package Insert, in. Summit, NJ, USA: Celgene Corporation, 2006.
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.Blood. 2006; 108: 2165
- Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma.J Clin Oncology. 2005; 23: 568S
THALOMID (thalidomide) Product Information, in. Summit, NJ, USA: Celgene Corporation, 2006.
- Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.Haematologica. 2005; 90: 1650
- A phase II study of PS-341 for patients with high risk, newly diagnosed multiple myeloma: a trial of the Eastern Cooperative Oncology Group (E2A02).Blood. 2005; 106: 715A
- Superiority of melphalan-prednisone (MP) plus thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma.J Clin Oncol. 2006; 24: 1S
- Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis.Blood. 2005; 106: 231A
- Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.Blood. 2006; 108: 2159
- Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B study 10301.Blood. 2006; 108: 239A
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.Lancet. 2006; 367: 825
- Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.Blood. 2005; 106: 2977
- Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.J Clin Oncol. 2006; 24: 431
- Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.Leuk Res. 2007; 31: 779
- Short survival, despite promising response rates, after bortezomib treatment of multiple myeloma patients with a 13q-deletion.Blood. 2005; 106: 152A
- Amplification of 1q21 is associated with poor outcome after treatment with bortezomib in relapsed/refractory multiple myeloma.Blood. 2006; 108: 970A
- Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.Leukemia. 2007; 21: 151
- Response to bortezomib and activation of osteoblasts in multiple myeloma.Clin Lymphoma Myeloma. 2006; 7: 109
Article info
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
